Alnylam Onpattro’s Expanded Use Gets Weak Thumbs Up From US FDA Panel

 
• By Sarah Karlin-Smith
baseball player bunting
Two FDA advisors described Alnylam’s Onpattro ATTR cardiomyopathy data as a 'bunt single' in lukewarm positive panel. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers